CXCR4 and diffuse large B-cell lymphoma: The T22-PE24 nanotoxin has already proved to be effective in targeting CXCR4+ cells in head and neck squamous cell carcinoma (HNSCC) (Rioja-Blanco et al., 2022a), diffuse large B-cell lymphoma cells (DLBCL) (Falgas et al., 2020a), colorectal cancer (CRC) (Sala et al., 2022), endometrial cancer (EC) (Medina-Gutierrez et al., 2022), and acute myelocytic leukemia (AML) (Nunez et al., 2023).